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Abstract
Alcohol and cannabis misuse is currently the most frequent co-morbidity
disorder of schizophrenia. The following four issues will be dealt with: 1) the
neurobiological basis of the psychosis-inducing, pathogenic effects of THC,
the agent contained in cannabis products. 2) Can cannabis use - and for
comparison alcohol abuse - prematurely trigger or even cause schizophrenia?
3) Are persons genetically liable to schizophrenia, psychosis-prone individuals
or young persons before completion of brain development at an increased
risk? 4) What consequences does cannabis use have on the symptomatology
and further course of schizophrenia?
Results from recent literature and the ABC Schizophrenia Study show that
the risk for cannabis use in schizophrenia is about twice the size in healthy
controls. In most cases cannabis use starts before first admission, in a third of
cases before schizophrenia onset. There is an increased affinity to misuse
already at the prodromal stage. Cannabis can prematurely trigger schizophrenia
onset – on average eight years earlier than in non-use - and cause the illness
partly in interaction with predisposing factors. Cannabis use in the course of
schizophrenia increases positive symptoms and reduces affective flattening,
thus leading to dysfunctional coping in some cases.
Key words: Psychosis and cannabis; co-morbidity; cannabis as a cause of
schizophrenia; cannabis as a trigger; pre-mature onset of schizophrenia; dual
diagnosis; schizophrenia and substance misuse.
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Introduction
Cannabis is a drug with pain-relieving, stimulating,
euphorising and erotogenic effects (Regier et al., 1990,
UNODC, 2004). Taken in higher doses, it leads to
impaired self-control and finally to psychosis or
sedation, disorientation and loss of conscience. In the
last two decades cannabis use markedly increased
particularly among adolescents, and age of onset fell
continuously in many countries. The age-related
incidence of illegal drug use in Germany makes plain
that cannabis is far ahead of other illegal drugs in
young age groups (Perkonigg et al., 1997) (Figure 1)
– meanwhile the curve has progressed to even younger
ages. At the same time delta-9-tetrahydrocannabinol
concentrations, the major psychoactive component of
cannabis in Western countries, increased nearly
tenfold in samples obtained on the market – for
54
Häfner, H. Rev. Psiq. Clín. 32 (2); 53-67, 2005
example in Switzerland from an average of 1% to 4 %
in 1995 and to 6 % to 28 % in 2003 (Bernhard 2004).
57 samples of cannabis products randomly bought by
Swiss television journalists on the illegal Swiss market
for an average price of 10 Fr/g in 2003 had an average
THC concentration of 14.5 % and a maximum of 25 %.
It is not unlikely that due to the drug’s increased
potency also the adverse effects of cannabis use, such
as psychosis triggered by cannabis, have increased
and as a result attracted increased awareness.
In addition to the effects mentioned low THC
doses have anxiolytic and antidepressive properties.
Higher doses have reversed effects: they are highly
anxiogenic and depressogenic. High THC doses can
produce schizophrenia-like psychoses, which usually
go without negative symptoms and remit after THC
has been excreted, mostly within one week of
abstinence (Mathers and Ghodse, 1992, McGuire et
al., 1994, Hall and Degenhardt, 2000, Johns, 2001).
The British Crime Report 2002 lists the public-
health risks associated with cannabis use: suicide,
risky sexual behaviour, increased teen and unwanted
pregnancies, sexually transmissible diseases,
homelessness, traffic accidents, accidents in general,
violent crime, crime in general, increased health costs
and mental problems and illness.
Cannabis and alcohol use are more prevalent
among people with schizophrenia than among healthy
controls and also more prevalent than in other mental
disorders. Apparently patients with schizophrenia in
this way try to get relief from the distressing
symptoms and adverse consequences of the disorder
or to offset these negative experiences by positive
moods and fantasies.
Table 1 lists 11 studies on cannabis use in
manifest schizophrenia and one review (Strakowski
et al., 1998). The frequency ranges from 4% to 86%.
The pronounced differences indicate that the
rates are not comparable at their face value. The
studies differ in scientific quality (Mueser et al.,
1992a,b), and their results are influenced by various
kinds of factors. First of all, how is drug use measured?
Lifetime prevalences depend on the length of the period
of risk covered and thus on the age of the probands
studied as well as on the duration of illness and
exposure to an excess risk. The increase in the
proportion of patients with cannabis and alcohol use
in the study of Soyka et al. (1993) from first admission
to several years later in a chronic course of
schizophrenia may serve as an example (Table 2).
When co-morbidity rates are compared across
different areas, countries or time periods, factors to
take into account are the availability of the drug in
question and the patterns of drug habit of the
populations studied. The availability and price of
illegal drugs in particular vary considerably. For this
reason, prevalence rates for both total populations and
patients with schizophrenia are hardly comparable
across geographic areas and different time periods.
What can be compared are relative risks, that is, the
Table 1. Cannabis use and dependence in patients treated for schizophrenia (mostly inpatients).
Author/Year of publication/Country Prevalence Specifications
Verdoux et al., 1996 (F) 25%
Menezes et al., 1996 (GB) 40% (at least once)
Strakowski et al., 1990-96 (review) (published in 1998) 8-42%
Modestin et al., 1997 (CH) 12%
Grech et al., 1998 (London) 39% (controls: 21.9%) (current use)
Wheatley, 1998 (GB) 51% (at least once in lifetime)
Sembhi and Lee, 1999 (Australia) 86% (lifetime, inpatients)
Mueser et al., 2000 (USA) ~50% (first episodes: 23-37%)
Duke et al., 2001 (London) 20% (at least once)
Hall & Degenhardt, 2002 (Australia) 12% (current use or addiction)
McCreadie et al., 2002 (Scotland) 4% (controls: 2%) (addiction)
Häfner et al., 2002 (Mannheim) 14% (controls: 7%) (lifetime at first admission, at least once)
Figure 1. Age-related incidence of illegal drug use
in Germany (Source:  Perkonigg et al. 1997).
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frequency of drug use in excess of that in a comparable
control population. A prerequisite for sound studies is
that adequately matched controls from the local
population are included. Unlike illicit drug use alcohol
misuse varies less, because alcohol is freely available
and low in price almost everywhere. For this reason
results on alcohol misuse in schizophrenia are more
or less comparable.
Neurobiological basis of THC effects
The THC effect is based on the highly-specific
neurobiological properties of the substance. THC binds
to G-protein-coupled cannabinoid receptors (CB-1). It
acts via the body’s own cannabinoid system in close
interaction with the dopamine neurotransmitter
system and accounts for both addictive behaviour and
therapeutic effects (pain and anxiety relief). The
highest density of CB-1 receptors is to be found in
those – primarily dopaminergic - brain areas and
pathways (depicted by arrows in figure 2) that are
mostly active in the production of schizophrenic
symptoms in the dorsolateral prefrontal cortex (Dean
et al., 2001): the limbic system, hippocampus, basal
ganglia and cerebellum (Leweke et al., 1999). The
endogenous cannabinoids enhanced by cannabis use
in people with schizophrenia (Leweke et al., 1999) are
also responsible for down-regulating the relase of
GABA, an inhibitory neurotransmitter, in the
hippocampal neurons (Wilson and Nicoll, 2001).
THC also increases dopamine activity in the
mesolimbic area and the nucleus accumbens. It is
this effect on the reward system that is responsible
for the addictive potency of THC (Figure 2).
THC induces the synthesis and release of
dopamine and inhibits dopamine reuptake in the
synaptic cleft. Repeated use of cannabis may increase
synaptic dopamine activity and as a consequence
produce prolonged changes in the cannabinoid system.
In addition, THC can lead to sensitization reflected in
flash-back phenomena (Figure 3). The psychotomimetic
potency and the localisation of THC dopamine receptor
activation point to a possible causal relationship
between cannabis use and schizophrenia. This
hypothesis has been pursued by several authors
(Andreasson et al., 1987, Arseneault et al., 2002, van
Os et al., 2002, Verdoux et al., 2003).
We studied the following questions: 1. Can cannabis
use prematurely trigger or cause psychosis? 2. Are
Table 2. Lifetime prevalence of alcohol and cannabis use in Bavaria.
Lifetime prevalence First-admission schizophrenia Chronic schizophrenia
Alcohol use 17.4 % 34.6 %
Cannabis use 21.8 % 42.9 %
Source: Soyka et al., 1993
Figure 2. The neurobiological basis of the
psychological effect of cannabis: dopaminergic
neurons involved in both schizophrenic psychosis
and cannabis (THC) effect (Source: Häfner, 2004).
Figure 3. THC sensitization.
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persons genetically liable to schizophrenia, psychosis-
prone individuals or young persons with immature
brains at an increased risk? 3. How does cannabis use
influence the symptoms and course of schizophrenia?
Onset of schizophrenia triggered by cannabis
Suitable designs for testing hypothesis no. 1 are:
1. Prevalence rates of schizophrenia in cannabis
users compared with non-users in community
surveys. This design will reveal the size of the
co-morbidity problem and probably support the
assumption of an excess risk for schizophrenia
associated with cannabis use. The design serves
the purpose of planning prevention and care and
generating hypotheses about causal associations.
2. The size and direction of the association between
cannabis use and increased risk for schizophrenia
are tested in prospective, controlled longitudinal
studies of population cohorts, mostly birth cohorts.
3. A third design - testing the sequence of cannabis use
and illness onset retrospectively and prospectively -
allows us to determine the temporal dimension of
premature precipitation, and to specify the type of
the causal association (direct versus indirect)
Results from prospective studies
Table 3 gives an overview of seven large-scale
population-cohort studies, three of them based on more
than 50,000 individuals each, but on male at-risk
populations only – conscripts in age group 16 to 17
years in Israel (Weiser et al., 2003) and 18 to 20 years
in Sweden. The studies covered a maximum exposure
period of 27 years (Zammit et al., 2002). In all these
studies comparisons with non-users drawn from the
same population cohorts showed that cannabis users
in general had an enhanced risk for schizophrenia
with odds ranging from 1.3 to 4.1 and a modal value
of about 2 (Häfner et al., 2002, Arseneault et al., 2004).
A series of objections have been raised against the
causal interpretation of the results of the first large-
scale Swedish conscript study (Andreasson et al., 1988).
When first published, this result was new and surprising
to those favouring the legalization of cannabis.
For example it was criticised that the study relied
on clinical diagnoses given at inpatient admission.
Consequently, the cases included might have been
contaminated with cannabis-induced psychoses. Another
point raised was that outcome was restricted to hospital
admission. Furthermore, confounding factors such as
concomitant use of other drugs, family history of mental
disorder or unfavourable social conditions, it was pointed
out, could explain the association. For this reason, in
almost all recent studies relevant confounding factors
have been taken into account. The odds adjusted to
confounders are marked by an asterisk in Table 3.
Considering the fact that the prepsychotic prodromal
stage of schizophrenia has a mean duration of 4.8 years
(Häfner et al., 1995) we pointed out that some of the
conscripts included in the study could have been suffering
from an undiagnosed prodromal stage of the disorder.
In an unknown proportion of the cases cannabis use,
unrelated to or possibly a consequence of the disorder,
could have been falsely counted as a causal risk factor
for the disorder. To make allowance for this criticism
the Swedish authors (Zammit et al., 2002) left the first
five years of the risk period following initial assessment
out of consideration. Although the risk rate was slightly
reduced, the odds ratios were still significant.
To provide more solid evidence for the causal
association Andreasson et al. (1989) analysed 8433
male conscripts from the Province of Stockholm by
taking four levels of cannabis use prior to first
assessment into account. Table 4 shows a clear-cut
dose-response relationship. The result provides very
strong evidence for a causal association in the sense
of a premature precipitation or causation of the illness.
Five of the seven population cohort studies into
cannabis use and psychosis risk provide at least
crude estimates of different levels of cannabis
consumption demonstrating that more frequent uses
are associated with significantly increased odds
ratios for developing psychosis.
A further result of great importance has been
yielded by the two New Zealand studies (Table 3). In
these studies initial assessments of boys and girls were
done in childhood, so it was possible to test whether
age at exposure – an early onset of cannabis use, for
example, before brain maturation – increases the risk
for psychosis. Animal studies have demonstrated that
puberty in rats is a vulnerable period with respect to
the adverse effects of cannabinoids (Schneider and
Koch, 2003, Henquet et al., 2004). The onset of
cannabis use before age 15 in the Dunedin study and
even before age 18 in the Christchurch (Fergusson et
al., 2003) study turned out to be associated with a
significantly greater psychosis risk than a later onset.
As a result, immature brains in the period of puberty
or in childhood and adolescence in general are more
susceptible to adverse cannabis effects and to an
elevated psychosis risk in the long term.
The third design for analysing the sequence of
substance use onset and schizophrenia onset includes
an operational assessment of symptoms, behaviour
and milestones of the evolving disorder.
To recall the pattern of early illness course, illness
onset must be defined by 1) the onset of psychotic
symptoms, which happens about one year before first
admission, and 2) by the onset of first signs of the
disorder, which, on average, takes place 4.8 years before
psychosis onset (Häfner et al., 1995) (Figure 4). This
leads to the following two subhypotheses:
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Cannabis use can trigger 1) a premature onset of
schizophrenia, i.e. first symptoms including the
prodromal stage, 2) psychosis without first producing a
prodromal stage of schizophrenia, which seems to tally
with the neurobiochemical mechanisms of THC activity.
Study design, samples and method
Figure 5 illustrates the study area and a population-
based sample of 232 first illness episodes of broadly
Table 3. Prospective population follow-up studies into cannabis use as a risk factor for schizophrenia.
Study Number Period of Cannabis use Odds ratio Definition
population/ studied risk covered of risk
Study Sex  Age
Israeli conscripts 50413 5 to 11 years Cannabis before 2 Inpatient admission
(Weiser et al., 2003) male first assessment because of
16 to 17 years (probands: 12.4%, schizophrenia
controls: 5.9%
Swedish conscripts 50053 15 years Cannabis before 2.3* Ditto ICD-8
(Andreasson et al., male first assessment 4.1*
1988, 1989) 18 to 20 years > 50-times
Swedish conscripts 50087 27 years Cannabis 1.3-1.5* Ditto DSM-IV
(Zammit et al., 2002) male > 50 times 3.1
18 to 20 years
New Zealand 1977 birth cohort: From birth to Cannabis 3.7 Psychosis
Christchurch Study 1265 male, female age 21 years ≤ age 18 y. 2.3 (1.8*) at follow-up
(Fergusson et al., 2003) (0 years) ≤ age 21 y.
(analysed up
to age 35 y.)
New Zealand Birth cohort From birth to Cannabis Schizophrenia
Dunedin Study 1037 age 18 to < age 15 y. 6.56* (total spectrum disorder
(Arseneault et al., 2004) male, female 26 years use: 2.34) at follow-up
11 years age ≥ 18 y. 3.12*
Dutch NEMESIS Population sample: 3 years (drug Cannabis 2.76* Psychosis at
Study(van Os et al., 2002) 4105 male, female use starting at follow-up (BPRS)
18 to 64 years age 16/17 years)
Henquet et al. (2004) Population 4 years Cannabis: 1.53* At least one or two
sample N=3021 ≥ 5 times+6 levels 2.23* core psychotic
(follow-up N=2437) of use+  +Sign. symptoms (M-CIDI)
male, female dose-response
14 to 24 years relationship
* Confounding factors (concomitant use of other drugs, mental disorder at entry into study or familial loading
for mental disorder, growing up in an urban environment etc.) were taken into account.
Modal value (relative increase in schizophrenia risk compared with risk in non-users)
across studies (differences in age and risk period not considered): 2.43 (Arseneault et al., 2004).
Table 4. Dose-response relationship substudy of the Swedish conscript study: frequency of cannabis use
and schizophrenia incidence in 8433 men from the Province of Stockholm.
Frequency of cannabis use Conscripts n (%) Diagnosed with schizophrenia (n) Odds ratio
0 6188 (80.4) 28 1.0
1-10 911 (11.8) 5 1.2
11-50 276 (3.6) 3 2.4
> 50 320 (4.2) 6 4.1
Source: Andreasson et al., 1989
defined schizophrenia in age range 12 to 59 years from
a semi-rural, semi-urban German population of some
1.5 million (for a detailed description of the sample
see Häfner et al., 1999b).
The retrospective part of the study is based on these
232 first illness episodes. In the prospective part we
studied a representative subsample of 115 from the above
sample of first illness episodes at five cross sections over
five years after first admission (Figure 6). 57 controls
randomly drawn from the population register of the
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Figure 4. The early stages of schizophrenia from first sign of mental disorder to first admission (ABC first-
episode sample N=232 (108 men, 124 women) Source: Häfner et al., 1995.
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Figure 5. ABC first-episode sample (Source: Häfner and Nowotny, 1995).
N (both sexes) N (male) N (female)
PSE Interviews 276 133 143
IRAOS Interviews 267 127 140
first episodes 232 108 124
Catchment Area of Rhine-Neckar District and Eastern Palatinate   ~ Mio. 1.5 inhabitants
Inclusion Criteria: Consecutive first admissions in any of the 10 psychiatric hospitals or units over 2 years
Clinical diagnosis: (ICD-9: 295, 297, 298.3, 298.4)
Exclusion Criteria: organic psychosis, severe mental retardation
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city of Mannheim were matched to 57 first-episode
cases by age and sex.
Premorbid development of drug and alcohol misuse
and the course of schizophrenia up to first admission
were assessed using the IRAOS (Häfner et al., 1992,
1999a, 2003). Onset of cannabis misuse was defined by
a habit pursued at least twice a weak over at least one
month. Onset of alcohol misuse was defined by PSE
criteria as heavy drinking causing problems with
family, absence from work or withdrawal symptoms
such as morning shakes. These definitions are more
or less identical with the ICD-10 criteria.
Further course was assessed using the FU-HSD
(WHO, 1980). Positive symptoms were measured by the
PSE-9 (Wing et al., 1974), negative symptoms by the
SANS (Andreasen, 1981), functional impairment by the
WHO-PIRS (Biehl et al., 1989) and social impairment
by the DAS-M (Jung et al., 1989, WHO, 1988).
Results
Of the 232 first illness episodes assessed at first
admission 23.7 % had a lifetime history of alcohol
misuse and 14.2 % a history of illicit drug use. The
corresponding figures for age – and sex – matched
controls were fairly exactly half these values: 12.3%
for alcohol misuse and 7 % for drug use. The odds
ratio of 2 is in line with results from comparable studies
(Addington and Addington, 1998, Weiser et al., 2003).
88% of the cases with drug use consumed
cannabis, whereas 58% misused alcohol. Other drugs
played a minor role. At 39% lifetime prevalence for
any type of substance use, including alcohol, at first
admission was markedly higher for men than for
women at 22%, which is in agreement with a majority
of studies on the topic.
Age at schizophrenia onset for both types of
substance use was compared with abstinent controls.
In patients with cannabis use schizophrenia onset
occurred at a mean age of 17.7 years and thus 8 years
earlier than in abstinent patients (mean age 25.7
years), in patients with alcohol use at a mean of age
21.7 years, that is, 4 years earlier than in abstinent
patients (Figure 7). The subsequent milestones of
evolving schizophrenia – first negative symptom, first
positive symptom etc. – show almost the same age
differences between the three groups.
For a further testing of our hypothesis we mapped
the sequence of cannabis or alcohol misuse onset and
schizophrenia onset as based on the two definitions –
onset of schizophrenia (= first sign of the disorder)
versus onset of psychosis (= emergence of first
psychotic symptom).
Depicted in the middle of the top of Figure 8 is the
month of illness onset and to the left and right of it the
frequencies of misuse onset in the years preceding and
following that month. In 27.6 % of cases drug use
started before the month of illness onset. In 34.6 %,
about a third of cases and a highly significant excess,
schizophrenia onset occurred in the same month as
cannabis use onset did. On the bottom of the figure the
month of illness onset is shown in greater detail,
compared with 12 preceding and 12 following months.
The figure clearly demonstrates the highly significant
excess in schizophrenia onsets in the month coinciding
with the first spell of cannabis misuse.
Testing the second subhypothesis postulating the
precipitation of psychosis onset we were surprised to
find no such association (Figure 9).
To conclude, it must be regarded as established
that a sufficient degree of cannabis use – in our study
at least two times a week over four weeks - is capable
of triggering a premature onset of schizophrenia, a
result well in agreement with the eight years lower
age of illness onset in cannabis users compared with
non-users. Unexpectedly, it is not the psychotic episode
that is triggered, but usually the disorder as such.
Figure 6. The ABC Schizophrenia Study: medium-
term course (Source: Häfner and an der Heiden, 1999).
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Figure 7. Age at the onset of schizophrenia in
substance users versus non-users (Source: Bühler et
al., 2002).
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Figure 8. Hypothesis 1: Precipitation of schizophrenia. Sequence of onset of substance use and appearance of
first sign of illness (Source: Bühler et al., 2002).
Cumulative: 27.5% Cumulative: 37.9%
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Figure 9. Hypothesis 2: Precipitation of psychosis. Sequence of onset of substance use and appearance of
first psychotic symptom (Source: Bühler et al., 2002).
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Considering the primarily dopaminergic effects of THC
and its localisation in various areas of the brain involved
in the production of psychotic symptoms we presume
that the prepsychotic prodromal stage and the
subsequent psychosis are produced by the same
underlying pathophysiological process. Precipitated by
THC, which interacts with the endogenous cannabinoid
system, that process brings forth prodromal symptoms
first and a psychotic episode later on.
For comparison we also performed the same
analysis on alcohol misuse. As figure 10 shows, there is
a temporal association between onset of alcohol misuse
and onset of schizophrenia. But the significant excess of
schizophrenia onsets in alcohol users is considerably
smaller than – exactly half of that –in cannabis users.
Considering the four years lower age of illness
onset in alcohol users than non-users – half the amount
of time in cannabis users – it is reasonable to presume
that alcohol misuse, too, can trigger – though more
rarely – a premature onset of schizophrenia. But this
hypothesis requires replication in further studies. An
alternative explanation holds that the onset of alcohol
misuse is an event more difficult to determine exactly
than the onset of cannabis use and is frequently
preceded by a period of slight excess consumption.
However, we did not find any substantial differences of
that sort between the two types of substance use. The
only difference was in the proportion of patients starting
misuse after the month of illness onset: 49% of alcohol
Figure 10. Sequence of onset of alcohol abuse and first sign of illness. (Source: Bühler et al., 2002).
users and 27% of cannabis users. But most of that
difference is explained by the fact that 34.6% of cannabis
users, but merely 18.2% of alcohol users – 16.4% fewer
of them – start the habit in the month of illness onset.
That larger proportion of onsets of alcohol misuse
following the month of illness onset can be regarded as
a consequence of the higher proportion of schizophrenia
onsets triggered by cannabis misuse, which means that
these cases are excluded from the pool of cases starting
the habit at a later stage.
Does cannabis use trigger schizophrenia
only in vulnerable persons?
In view of the conclusive evidence for the precipitation
of schizophrenia by cannabis use, we wondered whether
this is also the case in persons who otherwise would
not develop the disorder. The first aspect to test is a
premature onset versus causation. The almost linear,
dose-related increase in the odds ratios in the Swedish
conscript study is a strong argument for the causation
hypothesis. But the maximum age at first admission
covered in that study was 35 years (Zammit et al.,
2002). When a mean of 5 years of pre-psychotic illness
course is excluded, the risk period extends to age 30
years. Cannabis-induced schizophrenias have certainly
inflated the incidence rates of schizophrenia in the
young age range. But it cannot be ruled out altogether
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that as a consequence of that increase schizophrenia
incidence fell by the same measure in a higher age
range. A definitive proof would be provided by a study
covering the whole period of risk for schizophrenia or
an analysis of a sufficiently comprehensive age trend
of risk. An alternative epidemiological way of proving
it – comparisons of incidence rates across the entire
age range in sufficiently large, fully comparable
populations with versus without cannabis use – is
not feasible. Nor would such an approach be promising
because of the small number of excess cases of
schizophrenia triggered by cannabis use and their low
impact on total schizophrenia incidence and the fact
that the incidence rates show clear variation at least
of the same magnitude.
Another aspect of a possible causal relationship is
the question of genetic predisposition and its interaction
with cannabis exposure as factors contributing to the
risk for schizophrenia. Some studies found that patients
with schizophrenia and cannabis use or patients with
cannabis use and more severe illness courses have a
greater familial loading for schizophrenia (Tsuang et
al., 1982, McGuire et al., 1995).
The Scottish high-risk study (Miller et al., 2001)
proceeded from cases with at least two relatives
diagnosed with schizophrenia. In these probands
cannabis use was associated with a significantly
increased psychosis risk compared with controls.
The Dutch and the New Zealand studies used
the lifetime prevalence of single – at least one –
psychotic symptoms independent of psychotic illness
as an indicator of psychosis-proneness. In the
NEMESIS study (van Os et al., 2002, Krabbendam et
al., 2004) (N=7076) cannabis use in psychosis-prone
individuals increased psychosis risk at prospective 3-
year follow-up significantly from 7.7% to 15.3%,
whereas the equally defined psychosis risk for controls
– no predisposition, no cannabis use – was 1.5%.
Results from the New Zealand study (Arseneault et
al., 2002) (N=1037) based on a longer period of risk
(until age 26 years) and comparisons with cannabis-
using non-vulnerable individuals confirmed the
interaction between psychosis vulnerability and
cannabis use: 10.3% of the probands with cannabis
use until age 15 years and single psychotic symptoms
at initial assessment developed psychosis by age 26
years, whereas only 3% of the controls (cannabis use,
but no psychotic symptoms) did so. A more recent study
(Henquet et al., 2004) of 2437 persons, male and
female, aged 14 to 24 years from the German
population of Munich used the paranoid ideation and
psychoticism subscales of the M-CIDI (Wittchen et
al., 1998) as indicators of psychosis proneness. At 4-
year follow-up presence of one or two psychotic
symptoms was used as an outcome indicator. Table 5
shows the result, which, based on six levels of cannabis
consumption – reveals a clear dose-response
relationship. The proportion of cannabis users rose
from 13% at baseline merely to 14.8% at follow-up.
This result indicates that in young persons with a
psychopathologically defined disposition for psychosis
cannabis use also increases the risk for single psychotic
symptoms. Concerning the psychosis risk as such,
this conclusion has only moderate, no immediate
implications.
Finally, Verdoux et al. (2003) in an experimental
study showed the dependence of the acute cannabis effect
on similarly defined, pre-existing psychosis vulnerability.
In psychosis-prone individuals (at least one psychotic
symptom) single doses of cannabis had more
unfavourable effects, such as loss of libido, more anxiety,
unpleasant thoughts, delusions, feelings of thought
influence, compared with non-vulnerable persons. This
result, too, can be regarded as indicating that cannabis
lowers the threshold for psychotic experiences.
The impact of alcohol and drug use on the
course of schizophrenia
Our last piece of analysis focused on the consequences
substance use has on the illness course. Because of
the small case numbers in our follow-up sample of
115 first illness episodes of schizophrenia we had to
lump together the cases with cannabis and/or alcohol
use. 29 patients fulfilling these criteria were matched
with 29 abstinent patients from the same sample by
age and sex.
Table 5. Interaction of cannabis use and predisposition for psychosis.
Risk of psychotic symptoms at follow-up
> 5 doses of cannabis No cannabis use Difference in risk
(lifetime) at baseline at baseline
Patients without predisposition for psychosis 21 % 15 % 5.6 %
Patients with predisposition for psychosis 51 % 26 % 23.8 %
Source: Henquet et al. 2004, modified
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Drug and alcohol use in the early course of
schizophrenia are associated with significantly
increased psychotic symptoms not only in the first
episode, but also throughout the five-year course. We
studied which of the three categories of psychotic
symptoms in particular are affected. We counted the
number of months per year spent with hallucinations,
delusions or psychotic thought disorder in the five-year
period (Figure 11). This result, too, was clear-cut: in
all three categories the time spent with symptoms was
longer in cannabis users. In two of the three,
hallucinations and thought disorder, the difference was
significant. Figure 12 illustrates the mean CATEGO
DAH score, a measure of psychotic symptoms, at six
cross sections over five years. While this result is in
line with the few comparable follow-up studies on the
topic (Addington and Addington, 1998, Caspari, 1999),
van Os et al. (2002) and Verdoux et al. (2003) have
reported “less severe psychotic experiences” in persons
with schizophrenia who use cannabis.
In a well-designed study Spencer et al. (2002)
found that the relief of positive symptoms and side-
effects of medications was a key motive for the
maintenance of substance use in patients with
psychotic disorder. Judging the results of that study
it must be taken into account that only a small
number of patients were interviewed and a distinction
must be made between the frequency of symptoms,
such as hallucinations, and subjective distress
experienced by the patients. The latter is presumably
reduced as a result of the pain-relieving effect of
cannabis, whereas the frequency of symptoms is not
affected. Distress caused by side-effects of medications
and its reduction by cannabis use are relevant in
patients treated with classic neuroleptics.
We also studied the impact on negative
symptoms over five years. There was a slight, but
significant drop in the SANS global score. A detailed
analysis showed that this trend was largely accounted
Figure 12. Course of positive symptoms over 5 years after first admission for schizophrenia in patients with
substance use / non-use; analysis of variance with repeated measurements: substance use versus non-use: p=.003;
Zeit: p=.001; interaction time x substance use versus non-use: p=.123 (Source: Häfner et al., 1999b).
First adm. 6 months 1 year 2 years 3 years 5 years
DAH
Score
p<.02
p<.003
Figure 11. The impact of early-course substance
use on the frequency of psychotic symptoms over
5 years after first admission. First illness episodes
of schizophrenia (n=29) with substance use
compared with 29 age – and sex – matched
controls without the habit (Source: Bühler et al., 2002).
Months
per year
spent
with
symptoms
p<.003
3
2,5
2
1,5
1
0,5
0
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Hallucinations Delutions Psychotic thought
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14
12
10
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4
2
0
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p<.05
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for by a decrease in one particular symptom, affective
flattening (Figure 13). What our patients reported,
but we could not test for significance suggests that
cannabis makes feelings of indifference and emptiness
go away – these feelings are usually experienced as
more distressing than psychotic symptoms – thus
improving patients’ emotional responsiveness. This
seems to be the reason why some patients use cannabis
as a kind of self-therapy - in the sense of dysfunctional
coping – to combat a particularly distressing negative
symptom despite the fact that psychotic symptoms
increase as a consequence.
Compliance with prescribed medications in the
group with substance use was inadequate or non-
existent over a mean period of 33.6 months or 55.7%
of the follow-up period, whereas the corresponding
figure for controls was 24.6 months or 37.4%. The
number of days spent in inpatient care was 170 for
substance users and 131 for controls, but the difference
did not attain significance.
In contrast to most other studies, which report
not only more relapses and days spent in inpatient care
but also considerable social consequences (Addington
and Addington, 1998, Drake and Wallach, 1998,
Swofford et al., 1996, Linszen et al., 1994), we found
no significant differences in five-year social outcome
as based on regular employment between patients with
substance use versus non-use (Table 6). However, 57%
of the substance users, but merely 28% of the non-
users were unemployed. Surprisingly, this finding was
in part explained by the fact that 24% of the controls,
but only 4.8% of the substance users were in
rehabilitation. This difference might be accounted for
by the poorer compliance of substance users not only
with pharmacotherapy, but also with other types of
care. But it cannot be ruled out either that substance
users are more frequently turned down by
rehabilitation services because of their poorer prognosis.
The implication of these results is that timely and
appropriate rehabilitative measures accepted and
adhered to by the patients probably help to considerably
reduce the social consequences of the co-morbidity of
drug use and schizophrenia in the long term.
The social consequences of substance-use co-
morbidity in the early course of schizophrenia were
considerably smaller in our study than in other
controlled first-admission studies, e.g. Linszen et al.’s
(1994) in Amsterdam or Addington and Addington’s
(1998). One reason might be that ours was an
epidemiological first-episode sample, which comprised
Table 6. Early course substance use and occupational (training) status 5 years after first admission.
Patients with Employed In school or Unemployed In rehabilitation
vocational training
substance use 33.3% 4.8% 57.15%  4.8%
non-use 40.0% 8.0% 28.0% 24.0%
Source: Bühler et al., 2002
Figure 13. Course of affective flattening over 5 years after first admission for schizophrenia in patients with
substance use (n=29) / non-use (n=29) (Source: Bühler et al., 2002).
Mean
score
First adm. 6 months 1 year 2 years 3 years 5 years
p<.03
1,2
1
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